💥 Gate Square Event: #PostToWinFLK 💥
Post original content on Gate Square related to FLK, the HODLer Airdrop, or Launchpool, and get a chance to share 200 FLK rewards!
📅 Event Period: Oct 15, 2025, 10:00 – Oct 24, 2025, 16:00 UTC
📌 Related Campaigns:
HODLer Airdrop 👉 https://www.gate.com/announcements/article/47573
Launchpool 👉 https://www.gate.com/announcements/article/47592
FLK Campaign Collection 👉 https://www.gate.com/announcements/article/47586
📌 How to Participate:
1️⃣ Post original content related to FLK or one of the above campaigns (HODLer Airdrop / Launchpool).
2️⃣ Content mu
Hanyu Pharmaceutical: The enrollment of all subjects in the Phase III clinical trial for the weight loss indication of Semaglutide Injection has been completed.
On June 12, Hanyu Pharmaceutical said on the interactive platform that the company’s semaglutide injection was declared for marketing in accordance with Class 2.2, of which the bariatric indication had completed the enrollment of all subjects in the phase III clinical trial in January this year, and was currently in the follow-up stage, and the project had entered the dose maintenance period. After the completion of the Phase III clinical trial in the future, the Company will submit a marketing application after collating and improving the clinical trial data in accordance with relevant regulatory requirements.